We serve Chemical Name:1-Isothiocyanatobutane CAS:592-82-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-Isothiocyanatobutane
CAS.NO:592-82-5
Synonyms:Butane, 1-isothiocyanato-;MFCD00004824;BUTYL ISOTHIOCYANATE;1-Isothiocyanatobutane;EINECS 209-770-4
Molecular Formula:C5H9NS
Molecular Weight:115.197
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:168.0±0.0 °C at 760 mmHg
Density:0.9±0.1 g/cm3
Index of Refraction:1.484
PSA:44.45000
Exact Mass:115.045570
LogP:2.53
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1693 6.1/PG 2
Packing Group:III
Contact us for information like Butane, 1-isothiocyanato- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 209-770-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00004824 Use and application,MFCD00004824 technical grade,usp/ep/jp grade.
Related News: Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. 1-Isothiocyanatobutane manufacturer A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory. 1-Isothiocyanatobutane supplier Retrogenix holds two Queen��s Awards for Enterprise, the UK��s most prestigious acknowledgement of business performance. The company is headquartered near Manchester, UK, and has an office in Cambridge, MA. 1-Isothiocyanatobutane vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 1-Isothiocyanatobutane factory Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.
